Search for a trial

Non-randomised,open, multi-center trial evaluating feasibility and safety of Tachosil application on a colorectal anastomosis

The primary efficacy variable is if the TachoSil application was feasible. A feasible application implies that the entire TachoSil adhere, TachoSil covers at least 1 cm beyond the margins of the anastomosis line and if more TachoSil sponges are used…

A Phase 3, Open-label, Long-term Safety Study of Oral Linaclotide Administered to Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)

The objective of this study is to assess the long-term safety of linaclotide in pediatric participants with FC (total exposure with linaclotide for 24 weeks) or IBS-C (total exposure with linaclotide for 52 weeks) who have completed study…

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of Linaclotide Administered Orally to Children, Ages 6 to 17 Years, With Functional Constipation (FC)

To evaluate the safety and efficacy of 12 weeks of linaclotide therapy in comparison with placebo in pediatric participants aged 6 to 17 years who fulfill modified Rome III Criteria for Child/Adolescent FC

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in
the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn's Disease over a
Period of 24 Weeks and an Extended Follow-up Period for a Total of up to 52 Weeks.

This study has been transitioned to CTIS with ID 2023-503973-39-00 check the CTIS register for the current data. To evaluate the efficacy of darvadstrocel in combined remission at Week 24 for the treatment of complex perianal fistula in pediatric…

Longterm outcome of biological mesh closure of the pelvic floor after extralevator abdominoperineal resection for rectal cancer.

The aim of this study is to determine the cost-effectiveness of pelvic floor reconstruction using a biological mesh afterstandardized eAPR with neo-adjuvant (chemo)radiotherapy.